Bioinformatics: A Global Multi-Client Research Initiative
San Jose, California (PRWEB) July 18, 2014
Follow us on LinkedIn – GIA is pleased to announce the launch of a major research program analyzing the trends impacting the market for “Bioinformatics.” Invited to participate in this comprehensive grassroots level global research initiative are senior industry executives, domain experts, technologists. and market strategists. The new report to be issued shortly will offer accurate assessment of global market developments, including major technologies, trends, and challenges, together with descriptive, exploratory, and quantitative analysis of major product and geographic market segments. For details about how you can participate in this primary research program to include your inputs prior to the publication, please click here.
Rapid strides in the field of genomics have increased the volume of biological data on proteins and gene sequences. Optimum use of gene and protein-related information is critical in developing interactive drug development models that aid in decoding disease pathways and develop effective drug molecules. The penetration of genomics in drug discovery is expected to witness further growth, which bodes well for the bioinformatics market. Data management tools based on bioinformatics are helping companies ease the task of analyzing samples, thus enhancing productivity and efficiency in identifying new biomarkers for drug development. As pharmaceutical companies step up investments in R&D initiatives, bioinformatics is poised to witness strong growth. To increase the chances of successful development of potent drugs and reduce the risk of late stage drug failures, bioinformatics is increasingly used in every stage of R&D. The United States and Europe represent major markets for bioinformatics worldwide. Bioinformatics software is especially expected to witness steady growth fueled by effervescent innovation in software algorithms and growing focus of biotechnology companies on reducing costs and accelerating time-to-market of new drugs.
The upcoming report will offer coverage on major companies, including Affymetrix Inc., Agilent Technologies, Celera Group, Geneva Bioinformatics SA, IBM Life Sciences, and Life Technologies Corporation among others.
In addition, the study will also provide:
- Valuable market-based intelligence on new emerging trends, growth drivers, issues, and challenges
- Current coverage on company information and latest news and events, including strategic corporate developments and product innovations
- Fresh research perspectives, statistical findings, analyst analysis, and commentaries
- Accurate market estimates, projections, and forecasts across product segments (Software, Biocontent, and Hardware) and major geographic markets (the United States, Canada, Japan, Europe [France, Germany, Italy, the United Kingdom and Rest of Europe], Asia-Pacific [excluding Japan], and Rest of World).
About Global Industry Analysts, Inc.:
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends, while monitoring more than 126,000 companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/